76 related articles for article (PubMed ID: 3674759)
21. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
22. Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer.
Iwasaki A; Shirakusa T; Yamashita Y; Noritomi T; Maekawa T; Hamada T
Thorac Cardiovasc Surg; 2005 Dec; 53(6):358-64. PubMed ID: 16311973
[TBL] [Abstract][Full Text] [Related]
23. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
24. EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2004; 51(55):136-41. PubMed ID: 15011849
[TBL] [Abstract][Full Text] [Related]
25. [Radioimmunologic analysis of ferritin, carcinoembryonic antigen and prolactin for evaluating the prognosis and effectiveness of treating breast cancer].
Skliar SIu; Chebotareva ED; Ganul VL; Korolev VI
Med Radiol (Mosk); 1987 Oct; 32(10):32-6. PubMed ID: 3657434
[TBL] [Abstract][Full Text] [Related]
26. [Initial immunologic evaluations in breast and thyroid cancer].
Abeatici S; Mussa A; Levis P; Sandrucci S; Storta P
Minerva Med; 1982 Apr; 73(18):1149-54. PubMed ID: 6979010
[TBL] [Abstract][Full Text] [Related]
27. Indicative value of carcinoembryonic antigen (CEA) for liver recurrence following curative resection of stage II and III gastric cancer.
Ikeda Y; Mori M; Kajiyama K; Kamakura T; Maehara Y; Haraguchi Y; Sugimachi K
Hepatogastroenterology; 1996; 43(11):1281-7. PubMed ID: 8908563
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R
Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer.
Dearnaley DP; Patel S; Powles TJ; Coombes RC
Oncodev Biol Med; 1981; 2(4):305-11. PubMed ID: 7301610
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
31. Serial carcinoembryonic antigen (CEA) determinations in the management of patients with breast cancer.
Staab HJ; Ahlemann LM; Koch HL; Anderer FA
Oncodev Biol Med; 1980; 1(3):151-60. PubMed ID: 7279702
[TBL] [Abstract][Full Text] [Related]
32. Importance of serum prolactin determination in metastatic breast cancer patients.
Mujagić Z; Mujagić H
Croat Med J; 2004 Apr; 45(2):176-80. PubMed ID: 15103755
[TBL] [Abstract][Full Text] [Related]
33. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
34. Aminoglutethimide in the management of advanced breast cancer.
Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer C; Jones M; McKinna JA; Powles TJ
Eur J Cancer (1965); 1980; Suppl 1():99-101. PubMed ID: 7318876
[No Abstract] [Full Text] [Related]
35. Serum tumor markers in skeletal metastasis.
Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
37. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients.
Jäger W; Eibner K; Löffler B; Gleixner S; Krämer S
Anticancer Res; 2000; 20(6D):5179-82. PubMed ID: 11326691
[TBL] [Abstract][Full Text] [Related]
38. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
39. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
40. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
Willsher PC; Beaver J; Blamey RW; Robertson JF
Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
